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Abstract 
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that leads to a progressive 
decline in a person’s memory and ability to communicate and carry out daily activities. The brain 
pathology in AD is characterized by extensive neuronal loss, particularly of cholinergic neurons, 
intracellular neurofibrillary tangles composed of the tau protein (NFTs) and extracellular deposition of 
plaques composed of β-amyloid (Aβ), a cleavage product of the amyloid precursor protein (APP). These 
two insoluble protein aggregates are accompanied by a chronic inflammatory response and extensive 
oxidative damage. Whereas dys-regulation of APP expression or processing appears to be important for 
the familial, early-onset form of AD, controversy exists between the “Baptists” (in favour of Aβ) and the 
“Tauists” (in favour of tau) as to which of these two protein dysfunctions occur at the earliest stages or 
are the most important contributors to the disease process in sporadic AD. However, more and more 
“non-amyloid” and “non-tau” causes have been proposed, including, glycation, inflammation, oxidative 
stress and dys-regulation of the cell cycle. However, to get an insight into the ultimate cause of AD, and to 
prove that any drug target is valuable in AD, disease-relevant models giving insight into the pathogenic 
processes in AD are urgently needed. In the absence of a good animal model for sporadic AD, we propose 
in this review that induced pluripotent stem cells, derived from dermal fibroblasts of AD patients, and 
differentiated into cholinergic neurons, might be a promising novel tool for disease modelling and drug 
discovery for the sporadic form of AD. 
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Abstract  
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that 
leads to a progressive decline in a person’s memory and ability to communicate and 
carry out daily activities. The brain pathology in AD is characterized by extensive 
neuronal loss, particularly of cholinergic neurons, intracellular neurofibrillary tangles 
composed of the tau protein (NFTs) and extracellular deposition of plaques 
composed of β-amyloid (Aβ), a cleavage product of the amyloid precursor protein 
(APP). These two insoluble protein aggregates are accompanied by a chronic 
inflammatory response and extensive oxidative damage. Whereas dys-regulation of 
APP expression or processing appears to be important for the familial, early-onset 
form of AD, controversy exists between the “Baptists” (in favour of Aβ) and the 
“Tauists” (in favour of tau) as to which of these two protein dysfunctions occur at the 
earliest stages or are the most important contributors to the disease process in 
sporadic AD. However, more and more “non-amyloid” and “non-tau” causes have 
been proposed, including, glycation, inflammation, oxidative stress and dys-
regulation of the cell cycle. However, to get an insight into the ultimate cause of AD, 
and to prove that any drug target is valuable in AD, disease relevant models giving 
insight into the pathogenic processes in AD are urgently needed. In the absence of a 
good animal model for sporadic AD, we propose in this review that induced 
pluripotent stem cells (iPSCs), derived from dermal fibroblasts of AD patients, and 
differentiated into cholinergic neurons, might be a promising novel tool for disease 
modelling and drug discovery for the sporadic form of AD. 
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1. Alzheimer’s disease  
1.1  Alzheimer’s disease and the urgent need for early diagnosis and specific 
treatments  
Alzheimer’s disease (AD) is a progressive neurodegenerative brain disorder that 
leads to progressive decline in a person’s memory and ability to learn, make 
judgments, communicate and carry out daily activities. In the course of the disease, 
episodic memory is affected early, caused by neuronal dysfunction and cell death in 
the hippocampus and other medial temporal structures. As the disease progresses 
further, neurons also die in other cortical regions of the brain (Arendt 2009). At that 
stage, sufferers develop abnormalities in a range of cognitive domains as well as 
neuropsychiatric symptoms such as apathy, agitation or psychotic symptoms (Aalten 
et al. 2008). Patients with AD not only suffer emotionally and physically, but also 
represent a significant financial and emotional burden for caregivers, society and the 
community. Thus, it is becoming increasingly important to find the initial cause(s) of 
AD.  
Induced pluripotent stem cell (IPSC) technology, whereby a patient’s somatic cells 
can be reprogrammed to a pluripotent state by the forced expression of a defined set 
of transcription factors, may offer a way forward to the development of novel 
personalized neuroprotective therapies that prevent AD (Huber et al. 2006; 
Holmquist et al. 2007; Maczurek et al. 2008). In addition, a growing focus is on 
biomarkers which enable detection of the disease in its early stages and will allow for 
preventative treatment (Song et al. 2009).   
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1.2 Histopathology of Alzheimer’s disease – key to pathogenesis and therapy? 
The brain pathology in AD that is associated with cognitive decline and profound 
dementia is characterized by extensive neuronal loss, particularly of cholinergic 
neurons, intracellular neurofibrillary tangles (NFTs) and extracellular deposition of β-
amyloid (Aβ) plaques (Braak et al. 2004; Thal et al. 2006). These two insoluble 
protein aggregates accumulate in susceptible regions of the brain and are 
accompanied by a chronic inflammatory response and extensive oxidative damage 
(Sastre et al. 2006; Weisman et al. 2006; Fuller et al. 2010). 
Senile plaques, composed of crosslinked (e.g. by glycation or oxidation) β-amyloid 
(Aβ) peptide, are present in specific brain regions of AD patients (Loske et al. 2000; 
Thal et al. 2002). Aβ has been proposed to have a variety of toxic properties such as 
the ability to block communication between neurons, to cause degeneration of 
neurites, to contribute to oxidative stress and ultimately to lead to neuronal cell death 
(Kuhla et al. 2004). In addition, Aβ causes inflammation, as evidenced by the 
activation of the inflammatory cells of the brain, microglia and astroglia, mainly 
around the amyloid plaques (Wong et al. 2001).  
The second protein aggregation problem in AD is largely intracellular, and results 
from the deposition of neurofibrillary tangles in neurons. These tangles are mainly 
composed of the cytoskeletal protein tau, and it has been suggested that hyper-
phosphorylation and glycation contribute to their insolubility (Chen et al. 2004). In the 
CNS, tau is found in greatest abundance in neurons, where it stabilises microtubules 
and is therefore key to maintenance of axonal integrity. Hyper-phosphorylation leads 
to “neurofibrillary tangles”, destabilisation of the cytoskeleton, axonal degeneration 
and eventually neuronal cell death (Goedert et al. 1995; Gotz et al. 2010). Recent 
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studies suggest, that tauopathy in sporadic Alzheimer’s disease may begin in the 
third decade and possibly starts in the lower brainstem rather than in the 
transentorhinal region (Braak et al. 2011). 
Considerable controversy still continues amongst the “Baptists”, and the “Tauists” 
(favouring either amyloid or tau as the major contributor to the disease, respectively) 
as to which of these two protein dysfunctions occurs at the earliest stages or are the 
most important contributors to the disease process. In addition, more and more “non-
amyloid” and “non-tau” causes have been proposed, including disturbances in the 
insulin / insulin receptor glycation, inflammation, oxidative stress and dys-regulation 
of the cell cycle. Detailed descriptions of these “non-amyloid” and “non-tau” causes 
have been published in extensive reviews by the group of Peter Riederer and his 
collaborators (Thome et al. 1996; Münch et al. 1997; Münch et al. 1998; Retz et al. 
1998; Riederer et al. 2006; Arendt et al. 2010; Rahmadi et al. 2011; Srikanth et al. 
2011).  
 
1.2.1 Anti-amyloid drugs  
The most favoured hypothesis about the cause of AD is the ‘amyloid cascade 
hypothesis’. This hypothesis states that the aberrant production, aggregation and 
deposition of Aβ is the causative process in the pathogenesis of both familial and 
sporadic (late-onset) AD (FAD and LOAD) (Iwatsubo et al. 1994; Karran et al. 2011).   
Aβ is a proteolytic fragment of the amyloid precursor protein (APP). In the 
amyloidogenic pathway, APP is first cleaved by β-secretase (BACE1) to generate a 
slightly shorter N-terminal ectodomain, APPs-β (Borchelt et al. 1996; Scheuner et al. 
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1996; Tomita et al. 1997).  This is then cleaved by γ-secretase within the 
transmembrane domain to generate Aβ peptides of 40- and 42 amino acids in length 
(Gotz, Lim et al. 2010) .  
The view that Aβ plays a central role in AD pathogenesis has developed from 
observations that patients with mutations in the APP and presenilin (PSEN) genes 
show both accelerated plaque deposition and the onset of dementia at an early age, 
and that all these patients demonstrate an increase in the production of Aβ, 
particularly the longer and more aggregation prone Aβ 1-42 (Butterfield et al. 2002).  
Based on the “amyloid cascade hypothesis”, there was great hope to find a cure for 
AD by lowering the concentration of Aβ using a variety of different therapeutic 
approaches. Various “anti-amyloid drugs” targeting different pathways of Aβ42 
production and/or aggregation have been developed and tested in clinical trials with 
AD patients. Their mechanisms of action include:  
- Inhibiting the enzymatic actions of the secretases with β- and γ-secretase 
inhibitors, thereby lowering the production of Aβ (Imbimbo et al. 2011) 
- Changing the action of the γ-secretase and changing Aβ production from β1-
42 to shorter amyloid chain lengths  using amyloid modulators (Czirr et al. 2006) 
- Eliciting an anti-Aβ antibody response (active immunization) or providing 
recombinant Aβ antibodies (passive immunization), both leading to amyloid removal 
by the immune system (Münch et al. 2002; Robinson et al. 2004; Dasilva et al. 2006; 
Panza et al. 2010). 
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-  Metal chelators which dissipate A plaque deposits by chelating divalent metal 
ions (Fe2+, Cu2+ and Zn2+). A current example is clioquinol, with impressive effects in 
transgenic, APP overexpressing animal models and interesting results in phase I and 
II clinical trials (Bush 2002; Faux et al. 2010; Adlard et al. 2011; Bareggi et al. 2012) 
Unfortunately, all “anti-amyloid drug” candidates have so far failed to produce the 
expected therapeutic breakthroughs. They did, however, succeed in their effort to 
lower amyloid production and/or to remove amyloid plaques, but the cognitive 
decline in the treated patients did not slow down (Wan et al. 2009; Smith 2010; 
Castellani et al. 2011).  
These results suggest that Aβ might not be the dominant cause of sporadic AD (at 
least in some patients), and the “anti-amyloid approach” may not be an effective 
treatment for AD by itself, or may need to be given prophylactically (Golde et al. 
2011).  
1.2.2 Anti-tangle drugs 
Tau, the protein component of the neurofibrillary tangles, is a microtubule-associated 
protein. It is proposed that the neurofibrillary tangles are formed as a result of 
abnormal hyper-phosphorylation, caused by an imbalance of kinase and 
phosphatase activities (Goedert et al. 1995).  A variety of kinases involved in the 
hyper-phosphorylation of tau have been described. These include glycogen synthase 
kinase-3 (GSK-3), mitogen-activated protein kinase (MAP)-kinase and microtubule 
affinity-regulating kinase 1 (MARK1). In addition, an insufficient activity of protein 
phosphatases, especially protein phosphatase 2A (PP2A), has also been suggested 
to be responsible for hyper-phosphorylation of tau. Another approach to the inhibition 
8 | P a g e  
 
of tangle formation might be the inhibition of tau crosslinking e.g. by advanced 
glycation endproducts by the use of anti-glycation agents (Kuhla et al. 2007; 
Krautwald et al. 2010; Rahmadi et al. 2011). Furthermore, it has been suggested that 
microtubule (MT)-stabilizing drugs such as epothilone D (EpoD), which improve in 
existing tau pathology and related behavioral deficits in aged PS19 mice, might hold 
promise for the treatment of AD and related tauopathies  
Inhibitors of kinases and activators of phosphatases are the main classes of “anti-
tangle” drugs (Navarrete et al. 2011). Two “anti-tangle” drugs, the GSK-3 inhibitors 
Tideglusib (Noscira, Spain) and the tau aggregation inhibitor methylthioninium 
chloride, Rember (TauRx Therapeutics, Singapore), have been tested in phase II 
clinical trials with some positive results, but the results of large phase II trials are still 
outstanding.  
However, with growing uncertainty of the therapeutic potential of drugs targeting 
amyloid and tau, other novel therapies have recently been proposed, including those 
targeting glycation, oxidative stress and inflammation (Retz et al. 1998; Maczurek et 
al. 2008; Rahmadi, Steiner et al. 2011; Srikanth et al. 2011).  
However, to get an insight into the ultimate cause of AD, and to prove that any drug 
target is valuable in AD, disease relevant models giving insight into the pathogenic 
processes in AD are urgently needed. In the absence of a good animal model for 
sporadic AD, we propose in this review that induced pluripotent stem cells (iPSCs), 
derived from dermal fibroblasts of AD patients, and differentiated into cholinergic 
neurons, might be a promising novel tool for disease modelling and drug discovery 
particularly for the sporadic form of AD. In the following sections, we will introduce 
the concept of iPSCs and review recently published studies in which these cells were 
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used for AD disease modelling, and yielded interesting, and sometimes unexpected 
results.  
 
2. Induced pluripotent stem cells (iPSCs) as a key to disease pathogenesis and 
drug discovery  
2.1 Introduction to induced pluripotent stem cells (iPSCs) 
The discovery of induced pluripotent stem cells (iPSCs), whereby a patient’s somatic 
cells can be reprogrammed to a pluripotent state by the forced expression of a 
defined set of transcription factors, has the potential to enable in vitro disease 
modelling and be used for drug discovery programs. In 2006, it was demonstrated 
that retroviral-mediated introduction of four transcription factors into mouse 
fibroblasts could convert them into cells closely resembling pluripotent embryonic 
stem cells (ESCs)(Takahashi et al. 2006).  In that study, Yamanaka and his group 
found that the introduction of a combination of four transcription factors — octamer 
binding protein 4 (also known as Pou5f1), Sox2, Krüppel-like factor 4 (Klf4) and c-
Myc — into mouse fibroblasts was sufficient to induce the expression of endogenous 
pluripotency genes and thus reprogram the somatic cells to a new state with colony 
morphology, cell morphology, growth characteristics, gene expression and antigen 
expression similar to mouse ESCs.  This stunning discovery was quickly replicated 
using human somatic cells, with the Yamanaka and Daley groups employing 
essentially the same gene cocktail (Takahashi et al. 2007; Park et al. 2008) and the 
Thomson group using a slightly different one (i.e., OCT4, NANOG, SOX2 and LIN28) 
(Yu et al. 2007).  Further evidence that these reprogrammed cells are pluripotent 
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was achieved by demonstrating they are capable of germ-line transmission in 
chimeric mouse assays (Okita et al. 2007; Wernig et al. 2007). Importantly, this work 
also showed that use of c-Myc should be avoided in reprogramming gene cocktails, 
as reactivation of the exogenous c-Myc transgene can lead to tumour formation. 
The ability to reprogram human somatic cells to a pluripotent state provides a means 
to generate large numbers of patient-specific differentiated cells for both research 
and transplantation.  Equally important, this reprogramming technology also enables 
the production of disease-specific cells from confirmed patients with disorders 
without a clear pattern of inheritance (“sporadic” cases). Accordingly, our group and 
others have generated hiPSCs from patients with sporadic AD. These new hiPSC 
lines will enable investigation of the development and maintenance of cholinergic 
neurons in a context uniquely-related to AD, with the potential for high-throughput 
chemical screening to identify lead compounds for AD treatment (Fig. 1). In our 
hands, colonies of AD-iPSCs were morphologically indistinguishable from control 
(Co) iPSC and hESCs (Fig. 1A). Further characterization revealed that AD-iPSCs 
were genetically and phenotypically indistinguishable from control hESC/hiPSCs. 
Hypomethylated OCT4 promoter regions indicate successful reprogramming of AD-
Fibs (24.4% vs. 66.7%, Fig. 1B). Using immunofluorescence staining, feeder-free 
cultures of AD-iPSCs typically expressed undifferentiated pluripotent markers OCT4, 
NANOG, SSEA4 and TRA160 (Fig. 1C). Quantitative gene expression analyses of 
pluripotency-associated genes were not significantly different across all pluripotent 
cell lines. In contrast, parental fibroblasts (AD-Fib) expressed extremely low levels of 
NANOG, OCT4, SOX2 and GDF3, but had similar levels of CMYC and KLF4 
expression (Fig.  1D). Furthermore, extended feeder-free culture showed no 
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chromosomal abnormalities in ALZ1/ALZ7 as determined by standard G-banding 
karyotypic analysis (Fig. 1E).  
Although hiPSCs share key morphological and molecular characteristics with human 
embryonic stem cells (O'Connor et al. 2011), genetic and epigenetic differences 
have been identified (Bock et al. 2011; Nishino et al. 2011; Wang et al. 2011) 
For example, the reprogramming process and/or subsequent culture can result in 
random DNA alterations not present within the genome of the parent cell (Hayden 
2011).  Since random integration of the transgene might lead to clonal heterogeneity 
and possible functional diversity, it is recommended to validate findings from one 
hiPSC clone with multiple independently-derived hiPSC clones from the same 
patient (Sidhu 2011).  
2.2 Drug discovery for AD using iPSCs 
Another potential challenge for both high-throughput drug screening and 
developmental investigations of Alzheimer’s-specific hiPSC cell lines is the 
production of large numbers of highly purified, mature cholinergic neurons.  
Encouragingly, methods for differentiating and purifying cholinergic neurons from 
hiPSC cultures have been published though it is presently unclear whether these 
neurons are, or can be induced to become, fully mature (Israel et al. 2012). 
A further challenge for hiPSC-based investigation of neurological disorders is that 
these disorders manifest themselves within the complex 3-dimensional architecture 
of the brain.  This architecture is difficult to reproduce in vitro, leading to some 
limitations with in vitro drug screening for novel neurological pharmaceuticals.  
However, careful design of the drug screening assay parameters and detection 
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methods should enable identification and pre-clinical validation of new lead 
compounds that have the potential to at least delay, if not cure, progression of 
diseases such as Alzheimer’s disease (Grskovic et al. 2011).  
Although iPSC technology seems promising, several safety obstacles need to be 
addressed before iPSCs transits to the clinic; in particular, the risk of insertional 
mutagenesis when using integrative viruses and the transmission of pathogens when 
in media and/or feeder layers containing animal products. While transgene/viral-free 
methods have been developed, a majority of iPSCs are still derived on animal feeder 
layers, which offsets the benefits of a xeno-free autologous transplantation. The use 
of animal feeder layers also introduces inconsistent and variable reprogramming 
outcomes, making the screening of suitable, fully reprogrammed iPSC colonies labor 
intensive (Chan et al. 2009). This is reflected in iPSC lines generated under different 
experimental conditions and show varying degrees of differentiation into 
hematopoietic and neural lineages (Feng et al. 2010; Hu et al. 2010), which also 
limits its therapeutic potential. The use of defined media however, minimizes variable 
and/or inhibitory components present in serum and growth-factor secreting feeder 
cells. Consequently, some laboratories have generated iPSCs under feeder-free 
conditions by using extracellular matrices and serum-free media (Sun et al. 2009; 
Vallier et al. 2009; Vallier et al. 2009).  While the phenotypic outcomes have been 
tested, transcriptomic characterization of feeder-free derived iPSCs has not been 
fully explored. The advent of whole transcript gene expression microarrays was 
capitalized on to identify underlying molecular events that may underpin the 
differences between feeder-derived, feeder-free derived iPSCs and human 
embryonic stem cells (hESCs) propagated under identical conditions. We for the first 
time reported that feeder-free iPSCs (ff-iPSCs) resemble hESCs more than feeder 
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derived iPSCs (f-iPSCs) in terms of overall gene expression patterns governing 
pluripotency and other biological functions. The processes related to pluripotent 
signature in hESCs (ie, DNA replication and cell cycle) were substantially enriched in 
ff-iPSCs and expression of bivalent genes was lower (Chung et al. 2012). The 
advantages of a feeder-free defined system are such that homogenous populations 
of patient-specific pluripotent stem cells can be generated, batch-to-batch 
differences created by serum and feeder-cells can be eliminated and scale-up 
cultures can be easily carried out. This is of particular interest in regenerative 
medicine.  
2.3 AD disease modelling with iPSCs – identification of differences in cell 
phenotype and specific, AD-related cellular processes  
The key to modelling any human disease is the identification of a disease-specific 
unique cellular phenotype. The most successful examples of this strategy have used 
diseases that have strong genetic components and affect a highly defined cell type 
leading to a characteristic difference to an unaffected cell, e.g. for diseases with a 
known molecular mechanism, such as in spinal muscular atrophy, Hutchinson-
Gilford Progeria syndrome, familial Parkinson’s disease or Down syndrome (Ebben 
et al. 2011; Malpass 2011; Jung et al. 2012; Shi et al. 2012). 
Similarly, iPSCs have been created from patients with familial AD (FAD) 
characterized by mutations in APP, PSEN1 and PSEN2.  For example, Yagi et al. 
generated iPSCs from fibroblasts of AD patients with mutations in PSEN1 (A246E) 
and PSEN2 (N141I), and characterized their subsequent differentiation into neurons 
(Yagi et al. 2011). They found that FAD–iPSC-derived neurons showed increased 
Aβ42 secretion. Furthermore, secretion of Aβ42 from these neurons sharply 
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responds to γ-secretase inhibitors and modulators, indicating the potential for 
identification and validation of amyloid-lowering drugs (Yagi, Ito et al. 2011; Yahata 
et al. 2011).  
In a further study, it was shown that iPSC-derived neuronal cells express functional 
proteins involved in Aβ production, including amyloid precursor protein, β-secretase, 
and γ-secretase, and were capable of secreting Aβ into the conditioned media 
(Yahata, Asai et al. 2011). Although Aβ production was inhibited by β- and γ-
secretase Inhibitors and an NSAID, there were different susceptibilities to all three 
drugs between early and late differentiation stages (Yahata, Asai et al. 2011).  
In another study, Israel et al. created iPSCs from two patients with familial AD, both 
caused by a duplication of the amyloid-precursor protein gene (APP ; termed 
APPDp), two with sporadic AD (termed sAD1, sAD2) and two non-demented controls 
(Israel, Yuan et al. 2012). They showed that relative to controls, iPSC-derived, 
purified neurons from the two APPDp patients and patient sAD2 exhibited 
significantly higher levels of the pathological markers Aβ(1–40), phospho-tau (Thr 
231) and active glycogen synthase kinase-3 β. Neurons from these patients also 
accumulated large RAB5-positive early endosomes compared to controls, indicating 
an impairment of autophagy. Interestingly, they also showed that treatment of 
purified neurons with β-secretase inhibitors, but not γ-secretase inhibitors, caused 
significant reductions in phospho-Tau (Thr 231) and GSK-3β levels (Israel, Yuan et 
al. 2012).  
Encouragingly, methods for differentiation and purifying cholinergic neurons from 
hiPSC cultures have been published though it is presently unclear whether these 
neurons are, or can be induced to become, fully mature ”. Israel et al described in 
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their manuscript that differentiated and purified neurons contained glutamatergic, 
GABAergic and cholinergic neuronal subtypes (Israel, Yuan et al. 2012). However, 
the two manuscripts about AD-iPSCs disease modelling did not contain descriptions 
about validated differentiation methods for pure cultures of cholinergic neurons 
(Yagi, Ito et al. 2011; Israel, Yuan et al. 2012).  However, protocols published 
describing the differentiation of ESCs to cholinergic neurons might provide useful for 
the cholinergic differentiation of iPSCs (Bissonnette et al. 2011).  
These two studies demonstrate that iPSC technology can be used to observe patient 
specific phenotypes in vitro, which reflect both the familial and the sporadic forms of 
the disease in a remarkable manner.  
2.4 AD disease modelling with iPSCs – mapping differences in gene and 
protein expression  
Both Yagi et al. and Israel et al. used protocols that induce differentiation to multiple 
neuronal subtypes (Yagi, Ito et al. 2011; Israel, Yuan et al. 2012). However, in the 
early stages of AD there is a preferential loss of cholinergic neurons and their 
innervation of the hippocampus and neocortex (Schliebs et al. 2011).   
One of the most interesting questions is whether the neurons derived from iPSCs of 
AD patients can be differentiated into cholinergic neurons, by activating specific 
intracellular signalling pathways including repressor element 1-silencing transcription 
factor (REST) and its corepressor (CoREST) (Ooi et al. 2007). Furthermore, it will be 
interesting to find out if AD iPSCs are distinctly different from those from age and 
gender-matched healthy controls in terms of global expression of mRNA and protein.  
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The induction of pluripotency largely revert somatic cells to their embryonic or 
‘ground’ state. Using a developmental approach and disease-related perturbations or 
stressors, the life history of the disease can be recapitulated in vitro from iPSCs 
creating differentiable phenotypes.  The alternative approach of culturing adult stem 
cells without a pluripotent stage would certainly maintain epigenetic cellular memory 
but it would be subsequently difficult to separate disease ‘cause’ from ‘effect’ (Murrell 
et al. 2008; Valenzuela et al. 2008).  Similarly, the direct reprogramming of 
fibroblasts to neurons is likely to retain this ‘cell memory’ (Vierbuchen et al. 2010; 
Qiang et al. 2011).   
 
However, there are also limitations and drawbacks on the use of iPSCs for dsease 
modelling and drug discovery. One of the limiting factors in the utility of iPSC lines 
for drug discovery and safety is the considerable technical ‘noise’ obscuring the 
disease-related ‘signal’. A major contributor to this noise is the lack of consistency 
and poor target cell enrichment during iPSC differentiation. However, our feeder-free 
system for generating iPSCs offers a robust system for obtaining a homogeneous 
population of these cells that follow pluripotent signature patterns (Chung, Lin et al. 
2012). The other key paradigm to circumvent the poor signal problem, which may 
then be tailored to the disease could be stratification of samples based on genetics 
(monogenic vs. polygenic/sporadic) and clinical history (responders vs. non-
responders). A further problem is the large clonal variation of iPSCs, which requires 
the generation of a couple of clones from each patient and comparison of properties 
among these different clones to prove a general biological characteristic of the 
patient.  
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3. Outlook – personalised medicine for AD patients   
The use of iPSC cellular models is therefore likely to lead to novel insights into the 
pathogenesis of AD, and to help discover new drugs for its treatment and/or 
prevention.  Since these models are derived from individual patients, the cellular 
characteristics can be related to clinical features of the disease in that patient.  An 
individual’s variations in the disease process and their cellular response to drugs 
may be reflected in the cellular model. If this is shown to be the case, a patient’s 
treatment regimen in the future could conceivably be individualised, based on the 
behaviour of the cellular model. For example, in the study by Israel et al only 1 out of 
the 2 sporadic AD patients showed similarities to familial AD cell lines in terms of 
amyloid production, phospho-tau and active glycogen synthase kinase-3β levels 
(Israel, Yuan et al. 2012), suggesting aetiological heterogeneity in the sporadic 
cases with a potential for differential treatment. 
Defining AD subgroups with iPSC technology presents an excellent opportunity for a 
true personalised approach to the treatment of AD. However, using current 
reprogramming and differentiation technology, it is unlikely that generating individual 
neurons from hiPSC for every patient for treatment will be economically viable. It is 
more likely that use of newly derived AD-hiPSCs will enable in vitro disease 
modelling that then enables patient specific therapies based upon appropriate 
characterisation of AD patient groups by genetics and biomarker profile, and 
subsequent appropriate, targeted drug treatment.  
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Figure 1. Characterization of Alzheimer’s disease specific hiPSCs (AD-iPSCs).   
A) Colony morphologies of hiPSCs from a non-demented control (Co-iPSC) and a 
sporadic AD patient (AD-IPSC) under feeder-free conditions. Scale = 500 µm. B) 
OCT4 promoter DNA methylation analysis using bisulfite sequencing. (Open 
squares: unmethylated, closed squares: methylated). C) Immunofluorescence 
staining of typical undifferentiated Co-hiPSCs;nuclear/surface markers, OCT4, 
NANOG, TRA160, SSEA4. Scale = 200 µm. D) Gene expression analyses of 
pluripotency-related gene of a non-demented control (Co-iPSC), two sporadic AD 
patients (ALZ1 and ALZ 27), and the original AD fibroblast cultures (AD-Fib) using 
quantitative PCR. *** p< 0.0005  E) Standard G-banding karyotypic analysis of AD-
iPSCs after extended propagation under feeder-free conditions.  
 
